(RTTNews) - Arcutis Biotherapeutics Inc.'s (ARQT) ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of atopic dermatitis in individuals regardless of race, ethnicity, and Fitzpatrick skin types, as per subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials.
The Fitzpatrick skin type is a scale of I to VI that classifies the skin by its reaction to exposure to sunlight, with skin type I being pale white skin that always burns, does not tan, to VI being dark brown or black skin that never burns, always tans darkly. vIGA-AD Success was defined as vIGA-AD value of 0 or 1 plus a 2-grade improvement from baseline.ZORY
ZORYVE-treated patients also achieved a greater improvement in itch.
The Incidence of Treatment Emergent Adverse Events (TEAEs) was low in both ZORYVE- and vehicle-treated patients. The incidence of TEAEs in ZORYVE-treated patients was generally similar across subgroups. Local tolerability was also favorable. The most common adverse reactions were headache, nausea, application site pain, diarrhea, and vomiting.
ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.
ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
